Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments

Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events... Diabetes Ther (2018) 9:1431–1440 https://doi.org/10.1007/s13300-018-0443-z REVIEW Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments . . W. Ryan Powell Cindy L. Christiansen Donald R. Miller Received: April 11, 2018 / Published online: May 28, 2018 The Author(s) 2018 and experimental studies comparing the safety ABSTRACT of SUs to that of other diabetes medications in people with type 2 diabetes mellitus through Introduction: Among the most pressing clini- December 15, 2015. Studies with at least 1 year cal decisions in type 2 diabetes treatments are of follow-up, which explicitly examined major which drugs should be used after metformin is cardiovascular events or death in patients who no longer sufficient, and whether sulfonylureas showed no evidence of serious conditions at (SUs) should remain as a suitable second-line baseline, were selected for inclusion in meta- treatment. In this article we summarize current analyses. evidence on the long-term safety risks associ- Results: SU treatment was associated with an ated with SU therapy relative to other oral glu- elevated risk relative to treatment with met- cose-lowering therapies. formin (METF), thiazolidinedione (TZD), Methods: The MEDLINE database and Clini- dipeptidyl peptidase-4 inhibitor (DPP-4), and caltrials.gov were http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetes Therapy Springer Journals

Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments

Download PDF
10 pages

Loading next page...
 
/lp/springer_journal/meta-analysis-of-sulfonylurea-therapy-on-long-term-risk-of-mortality-mNikPWN1jb
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Diabetes; Cardiology; Endocrinology
ISSN
1869-6953
eISSN
1869-6961
DOI
10.1007/s13300-018-0443-z
Publisher site
See Article on Publisher Site

Abstract

Diabetes Ther (2018) 9:1431–1440 https://doi.org/10.1007/s13300-018-0443-z REVIEW Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments . . W. Ryan Powell Cindy L. Christiansen Donald R. Miller Received: April 11, 2018 / Published online: May 28, 2018 The Author(s) 2018 and experimental studies comparing the safety ABSTRACT of SUs to that of other diabetes medications in people with type 2 diabetes mellitus through Introduction: Among the most pressing clini- December 15, 2015. Studies with at least 1 year cal decisions in type 2 diabetes treatments are of follow-up, which explicitly examined major which drugs should be used after metformin is cardiovascular events or death in patients who no longer sufficient, and whether sulfonylureas showed no evidence of serious conditions at (SUs) should remain as a suitable second-line baseline, were selected for inclusion in meta- treatment. In this article we summarize current analyses. evidence on the long-term safety risks associ- Results: SU treatment was associated with an ated with SU therapy relative to other oral glu- elevated risk relative to treatment with met- cose-lowering therapies. formin (METF), thiazolidinedione (TZD), Methods: The MEDLINE database and Clini- dipeptidyl peptidase-4 inhibitor (DPP-4), and caltrials.gov were

Journal

Diabetes Therapy – Springer Journals

Published: May 28, 2018

References

  • Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well!
    Abrahamson, MJ
  • Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it’s time to move on!
    Genuth, S
  • Assessing the quality of reports of randomized clinical trials: is blinding necessary?
    Jadad, AR; Moore, RA; Carroll, D
  • Introduction to meta-analysis
    Borenstein, M; Hedges, LV; Higgins, JPT; Rothstein, HR
  • Bayesian methods for the cross-design synthesis of epidemiological and toxicological evidence
    Peters, JL; Rushton, L; Sutton, AJ; Jones, DR; Abrams, KR; Mugglestone, MA
  • Measuring inconsistency in meta-analyses
    Higgins, JPT; Thompson, SG; Deeks, JJ; Altman, DG
  • Bias in meta-analysis detected by a simple, graphical test
    Egger, M; Davey Smith, G; Schneider, M; Minder, C
  • Updated tests for small-study effects in meta-analyses
    Harbord, RM; Harris, RJ; Sterne, JAC
  • Tissue specificity of sulfonylureas: studies on cloned cardiac and β-cell K(ATP) channels
    Gribble, FM; Tucker, SJ; Seino, S; Ashcroft, FM
  • More than 7 years of hindsight: revisiting the FDA’s 2008 guidance on cardiovascular outcomes trials for Type 2 diabetes medications
    Regier, EE; Venkat, MV; Close, KL
  • Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
    Vaccaro, O; Masulli, M; Nicolucci, A
  • Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE)
    Nathan, DM; Buse, JB; Kahn, SE
  • Bayesian methods for evidence evaluation
    Goodman, SN